Arcutis Biotherapeutics Inc. (ARQT) stock is soaring 6.71% in pre-market trading on Thursday, building on its impressive 6.12% gain during Wednesday's intraday session. The surge comes on the heels of the company's strong second-quarter 2025 financial results and significant business developments announced the previous day.
The biopharmaceutical company, which focuses on innovative dermatological therapies, reported better-than-expected Q2 earnings with an adjusted loss of 13 cents per share, outperforming analyst estimates of a 16 cents per share loss. This marks a substantial improvement from the 42 cents per share loss in the same quarter last year. Arcutis's revenue skyrocketed by 164.1% to $81.50 million, surpassing Wall Street's expectations of $73.69 million, driven primarily by strong demand for its flagship product, ZORYVE® (roflumilast) for plaque psoriasis treatment.
Adding to the positive momentum, Arcutis announced FDA approval for ZORYVE foam 0.3% to treat plaque psoriasis of the scalp and body in adults and adolescents aged 12 and older. The company also initiated the INTEGUMENT-INFANT study for ZORYVE cream 0.05% in infants with atopic dermatitis and submitted an Investigational New Drug Application for ARQ-234, a novel fusion protein for atopic dermatitis. These developments, coupled with a reiterated Buy rating from Mizuho Securities analyst Uy Ear with a price target of $21.00, are fueling investor optimism and contributing to the stock's pre-market rally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.